IRWD - חוב כולל להון Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals (IRWD) is accelerating the search for new formulas through AI screening and production automation, although final trials remain the responsibility of physicians. Simultaneously, the brand is implementing ESG principles, minimizing environmental impact during drug development and optimizing logistics. This historical price chart on GURU.Markets shows a debt-to-equity ratio of 0.00, while stable sales of Linzess enable the company to retain top talent.

The total liabilities-to-equity ratio determines the degree of financial leverage and the stability of the balance sheet structure. This coefficient measures the business's dependence on borrowed funds relative to net assets. By analyzing this chart of the total debt-to-equity ratio, an investor assesses the risk of bankruptcy in the event of a revenue decline. For Ironwood Pharmaceuticals (IRWD), a low level of indebtedness is critically important when renewing patent protection for key drugs. This guarantees resources for the development of new products without the risk of forced asset sales.